Comera Life Sciences Holdings, Inc.: Nasdaq/NYSE listing notice — Nasdaq warns Comera Life Sciences of MVLS deficiency; 180-day cure period ends May 17, 2023

Comera Life Sciences Holdings, Inc.

MVLS has been below $35M minimum for 30 consecutive business days, violating Nasdaq rule 5550(b)(2).
Compliance period runs until May 17, 2023; must close at $35M+ for ten consecutive days.
Alternative: meet minimum stockholders' equity of $2.5M to regain compliance.
No immediate impact on listing; stock continues trading on Nasdaq Capital Market under CMRA.
Company will monitor and evaluate options, but delisting risk remains if deficiency not cured.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Comera Life Sciences Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

November 18, 2022, Comera Life Sciences Holdings, Inc. (the “Company”) received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq listing rule 5550(b)(2). The notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Cap

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-292016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.